Autres langues Belite Bio, Inc

Actions

BLTE

US07782B1044

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
38 ^USD	+1,96 %		+9,83 %	-16,94 %

22/03	Belite Bio complète la soumission réglementaire pour l'essai clinique de Tinlarebant au Japon	MT
22/03	Belite Bio, Inc. annonce la soumission à la PMDA de Tinlarebant pour un essai clinique sur la maladie de Stargardt au Japon	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan	22/04
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom	18/04
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease	25/03
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	22/03
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22/03
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22/03
ADRs End Higher, ATRenew Inc. Climbs 26.9%	12/03
Belite Bio's Q4 Loss Narrows	12/03
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website	12/03
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12/03
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results	06/03
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results	06/03
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference	04/03
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference	04/03
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Belite Bio Gets Clearance to Launch Tinlarebant Phase 3 Trial for Eye Disease in China	27/12
Belite Bio : Receives Approval to Initiate Tinlarebant Phase 3 Clinical Trial for GA in China	27/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Belite Bio, Inc

Actions

BLTE

US07782B1044

Autres langues

Filtres